SNCA

SNCA. The SNCA gene provides instructions for making a small protein called alpha-synuclein, which is abundantly expressed in the brain and concentrated at presynaptic terminals. While its precise physiological function remains an active area of investigation, it is implicated in the regulation of synaptic vesicle trafficking and neurotransmitter release. The protein is most famously known as the primary structural component of Lewy bodies, the pathological hallmark of Parkinson's disease, and its misfolding and aggregation are central to a group of disorders known as synucleinopathies.

Gene and protein structure

The SNCA gene is located on the long arm of chromosome 4 at position 22.1, spanning approximately 117 kilobases and consisting of six exons. The translated protein, alpha-synuclein, is a 140-amino acid intrinsically disordered protein that lacks a stable tertiary structure under physiological conditions, a characteristic that contributes to its propensity for misfolding. Its primary structure can be divided into three distinct regions: an N-terminal amphipathic region containing imperfect repeats with a consensus KTKEGV sequence, a central hydrophobic region known as the NAC region (non-amyloid-β component), and an acidic C-terminal tail. This structure allows it to adopt an alpha-helical conformation upon binding to lipid membranes, such as those of synaptic vesicles, which is crucial for its normal function. The gene is highly conserved across vertebrates, underscoring its important biological role.

Function and physiological role

Under normal conditions, alpha-synuclein is a soluble, cytosolic protein that localizes predominantly to the presynaptic terminal of neurons. It is believed to play a key role in the regulation of synaptic vesicle pool size and the recycling of vesicles during the neurotransmission cycle. Research suggests it functions as a molecular chaperone for the SNARE complex assembly, facilitating the docking and fusion of vesicles with the presynaptic membrane. Its interaction with phospholipids and proteins like synapsin III and tubulin further supports a role in maintaining synaptic plasticity. While it is expressed throughout the brain, highest levels are found in the neocortex, hippocampus, substantia nigra, thalamus, and cerebellum. Its precise function, however, is complex and may involve responses to cellular stress.

Role in Parkinson's disease

The pathological aggregation of alpha-synuclein is the defining molecular event in the pathogenesis of Parkinson's disease and related disorders like dementia with Lewy bodies and multiple system atrophy. In these synucleinopathies, the protein misfolds, forms oligomers, and assembles into amyloid fibrils that accumulate within neurons as Lewy bodies and Lewy neurites. This process is thought to be driven by factors such as oxidative stress, mitochondrial dysfunction, and impaired protein degradation pathways involving the ubiquitin-proteasome system and autophagy. The resulting aggregates are cytotoxic, leading to synaptic failure, disruption of axonal transport, and ultimately, the degeneration of dopaminergic neurons in the substantia nigra pars compacta, which causes the characteristic motor symptoms of Parkinson's disease.

Genetic variants and mutations

Both point mutations and multiplications (duplications and triplications) of the SNCA gene cause rare, autosomal dominant forms of familial Parkinson's disease. The first identified pathogenic mutations were missense changes, including A53T, A30P, E46K, H50Q, and G51D. Gene multiplications lead to a dose-dependent increase in alpha-synuclein expression, with triplications causing a more severe, early-onset phenotype compared to duplications, directly supporting the hypothesis that protein overexpression drives pathogenicity. Furthermore, common genetic variability in the SNCA locus, including single-nucleotide polymorphisms in the promoter and 3' regions, is a significant risk factor for the sporadic, common form of Parkinson's disease, as identified in large genome-wide association studies.

Animal models and research

To study the mechanisms of synucleinopathy, numerous transgenic and viral vector-based animal models have been developed, primarily in organisms like mice, fruit flies, and nematodes. These models often involve overexpression of human wild-type or mutant alpha-synuclein and recapitulate key features of disease, such as protein aggregation, progressive neurodegeneration, and motor deficits. Research using these models has been instrumental in testing potential therapeutic strategies, including immunotherapy with anti-alpha-synuclein antibodies, gene silencing approaches like antisense oligonucleotides, and small molecules aimed at inhibiting aggregation or enhancing clearance pathways. Studies in yeast and primary neuronal culture systems have also provided fundamental insights into the cellular toxicity of oligomeric species. Category:Genes on human chromosome 4 Category:Parkinson's disease